Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

<p>The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion. </p> <p> </p>